Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
NCT00091702
Completed
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/28/2021
Locations: Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California +7 locations
Conditions: HIV Infections, Influenza
Register for Updates
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
NCT00000829
Completed
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects. To assess whether this vaccine is more immunogenic than placebo following the third vaccination. Children with HIV infection are at increased risk for invasive pneumococcal infection, particularly bacteremia. A large proportion of pneumococcal disease is caused by a limited number of serotypes. The maximu... Read More
Gender:
ALL
Ages:
Between 2 months and 6 months
Trial Updated:
10/27/2021
Locations: Usc La Nichd Crs, Los Angeles, California +4 locations
Conditions: HIV Infections, Pneumococcal Infections
Register for Updates
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
NCT00801697
Completed
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
NCT02207920
Completed
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
NCT00865566
Terminated
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men. NOTES: As of April 2013, all vaccinations in this study have been stopped. As of June 2017, this study has been closed.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: The AIDS Research Alliance of America CRS, Los Angeles, California +2 locations
Conditions: HIV Infections
Register for Updates
Early Immune Responses to Vaccination - A Substudy to HVTN 205
NCT00908323
Completed
HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
NCT01479296
Completed
The purpose of this study is to evaluate the immune response to the Vaccine Research Center (VRC) rAd5 HIV vaccine when the vaccine components are administered in three different ways, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
NCT01571960
Completed
This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NCT01783977
Completed
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/13/2021
Locations: Bridge HIV CRS, San Francisco, California
Conditions: HIV Infections
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: Clinical Office - Jason Cuellar M.D., Beverly Hills, California +23 locations
Conditions: Staphylococcal Vaccine
Register for Updates
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
NCT04540185
Unknown
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2020
Locations: Coronavirus Research Institute- Testing Site, Los Angeles, California +5 locations
Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Register for Updates
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460
Completed
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/21/2020
Locations: UC San Diego Moores Cancer Center, La Jolla, California +4 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
Register for Updates